Literature DB >> 15947890

Effects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytes.

Martin Wehling1.   

Abstract

Genomic mechanisms of mineralocorticoid action have been increasingly elucidated over the past four decades. In renal epithelia, the main effect is an increase in sodium transport through activation and de novo synthesis of epithelial sodium channels. This leads to increased concentrations of intracellular sodium activating sodium-potassium-ATPase molecules mainly at the basolateral membrane which extrude sodium back into the blood stream. In contrast, rapid steroid actions have been widely recognized only recently. The present article summarizes both traditional and rapid effects of mineralocorticoid hormones on intracellular electrolytes, e.g. free intracellular calcium in vascular smooth muscle cells as determined by fura 2 spectrofluorometry in single cultured cells from rat aorta. Latter effects are almost immediate, reach a plateau after only 3 to 5 minutes and are characterized by high specificity for mineralocorticoids versus glucocorticoids. The effect of aldosterone is blocked by neomycin and short-term treatment with phorbol esters but augmented by staurosporine, indicating an involvement of phospholipase C and protein kinase C. The Ca(2+) effect appears to involve the release of intracellular Ca(2+), as shown by the inhibitory effect of thapsigargin. This mechanism operates at physiological subnanomolar aldosterone concentrations and appears to result in rapid fine tuning of cardiovascular responsivity. As a landmark feature of these rapid effects, insensitivity to classic antimineralocorticosteroids, e.g. spironolactone or canrenone has been found in the majority of observations. In an integrated view, mineralocorticoids seem to mainly effect intracellular electrolytes genomically to induce transepithelial transport, and induce nongenomically mediated alterations of cell function (e.g. vasoconstriction) by rapid effects on intracellular electrolytes such as free intracellular calcium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947890     DOI: 10.1007/s10741-005-2347-z

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  64 in total

1.  Endometrial cell calcium and oestrogen action.

Authors:  R J Pietras; C M Szego
Journal:  Nature       Date:  1975-01-31       Impact factor: 49.962

2.  ON THE MECHANISM OF ACTION OF ALDOSTERONE ON SODIUM TRANSPORT: THE ROLE OF PROTEIN SYNTHESIS.

Authors:  I S EDELMAN; R BOGOROCH; G A PORTER
Journal:  Proc Natl Acad Sci U S A       Date:  1963-12       Impact factor: 11.205

Review 3.  SGK1 regulation of epithelial sodium transport.

Authors:  David Pearce
Journal:  Cell Physiol Biochem       Date:  2003

4.  Aldosterone-induced increase in the abundance of Na+ channel subunits.

Authors:  C Asher; H Wald; B C Rossier; H Garty
Journal:  Am J Physiol       Date:  1996-08

5.  Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells.

Authors:  R J Pietras; C M Szego
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

Review 6.  Nongenomic steroid action: controversies, questions, and answers.

Authors:  Ralf M Losel; Elisabeth Falkenstein; Martin Feuring; Armin Schultz; Hanns-Christian Tillmann; Karin Rossol-Haseroth; Martin Wehling
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

7.  Dissociation in plasma renin and adrenal ANG II and aldosterone responses to sodium restriction in rats.

Authors:  A Menachery; L M Braley; I Kifor; R Gleason; G H Williams
Journal:  Am J Physiol       Date:  1991-10

8.  Long-term mineralocorticoid-induced changes in rat neuron properties plus interaction of aldosterone and ANG II.

Authors:  S N Thornton; S Nicolaïdis
Journal:  Am J Physiol       Date:  1994-02

9.  Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Authors:  T Mune; F M Rogerson; H Nikkilä; A K Agarwal; P C White
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

10.  Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action.

Authors:  M Wehling; M Christ; K Theisen
Journal:  Am J Physiol       Date:  1992-11
View more
  7 in total

Review 1.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 2.  Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.

Authors:  Brent N Reed; Sarah E Street; Brian C Jensen
Journal:  Heart Fail Clin       Date:  2014-08-14       Impact factor: 3.179

Review 3.  Aldosterone and the vasculature: mechanisms mediating resistant hypertension.

Authors:  Daniel A Duprez
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

4.  Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain.

Authors:  Alvaro Yogi; Glaucia E Callera; Sarah O'Connor; Tayze T Antunes; William Valinsky; Perrine Miquel; Augusto C I Montezano; Anne-Laure Perraud; Carsten Schmitz; Alvin Shrier; Rhian M Touyz
Journal:  Cell Signal       Date:  2013-07-06       Impact factor: 4.315

Review 5.  Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.

Authors:  Juan Carlos Yugar-Toledo; Rodrigo Modolo; Ana Paula de Faria; Heitor Moreno
Journal:  Vasc Health Risk Manag       Date:  2017-10-16

6.  The effects of diuretics on intracellular Ca2+ dynamics of arteriole smooth muscles as revealed by laser confocal microscopy.

Authors:  Yasunori Tamagawa; Tomoyuki Saino; Makoto Matsuura; Yoh-ichi Satoh
Journal:  Acta Histochem Cytochem       Date:  2009-08-11       Impact factor: 1.938

Review 7.  Why are mineralocorticoid receptor antagonists cardioprotective?

Authors:  Wenxia Chai; A H Jan Danser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-31       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.